Discovery Technologies

Genovac’s core technology, genetic immunization, enables the development of antibodies against any protein target directly from DNA, an electronic sequence, or an accession number.

With Genovac as your partner, you have the freedom to work in multiple wild type and human-Ig transgenic species and strains. Use the strain and species of your choice or use multiple species to increase your chances of success.

Genovac is the premier research partner offering multiple automated single B cell antibody discovery platforms for rare antibody discovery, including Bruker’s Beacon^®, Genovac Nano^™, and the 10X Genomics ChromiumX + NGS single B cell screening and selection platforms.

Highly efficient semi-solid and well-based fusion options provide rapid delivery of antibodies that are comparable to yields of manual single B cell platforms.

GenovacAI^TM uses a next-generation generative deep learning algorithms to humanize antibodies with very high success rates. Combined with our high-throughput antibody production and characterization platforms, GenovacAI enables humanization of one-to-many candidate antibodies with significant savings in cost and time.

Genovac offers in-house hybridoma and single B cell antibody sequencing. Reliable antibody sequencing is critical to lead discovery and the development of therapeutic antibodies. Genovac understands that knowledge of the variable regions is an obligatory entry point for humanization.